zanubrutinib - Profile

What are the generic drug sources for zanubrutinib and what is the scope of patent protection?

Zanubrutinib is the generic ingredient in one branded drug marketed by Beone Medicines Usa and is included in two NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Zanubrutinib has one hundred and seven patent family members in thirty-two countries.

Summary for zanubrutinib

International Patents:	107
US Patents:	13
Tradenames:	1
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for zanubrutinib

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for zanubrutinib

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY

Dosage:

CAPSULE;ORAL

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for ZANUBRUTINIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BRUKINSA	Tablets	zanubrutinib	160 mg	218785	1	2025-11-13
BRUKINSA	Capsules	zanubrutinib	80 mg	213217	2	2023-11-14

US Patents and Regulatory Information for zanubrutinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No			Y	Y
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No			Y

EU/EMA Drug Approvals for zanubrutinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
BeiGene Ireland Ltd	Brukinsa	zanubrutinib	EMEA/H/C/004978Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).	Authorised	no	no	no	2021-11-22

International Patents for zanubrutinib

Country	Patent Number	Title	Estimated Expiration
Australia	2014256633
Brazil	112015025260
Canada	2902686
China	104884458
Cyprus	1118834
Cyprus	2022004
Denmark	2989106

Supplementary Protection Certificates for zanubrutinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2989106	PA2022504	Lithuania		PRODUCT NAME: ZANUBRUTINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1576 20211121
2989106	CR 2022 00008	Denmark		PRODUCT NAME: ZANUBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1576 20211123
2989106	C20220008 00459	Estonia		PRODUCT NAME: ZANUBRUTINIIB;REG NO/DATE: EU/1/21/1576; 23.11.2021
2989106	C202230011	Spain		PRODUCT NAME: ZANUBRUTINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF AUTHORISATION: 20211122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1576; DATE OF FIRST AUTHORISATION IN EEA: 20211122
2989106	PA2022504,C2989106	Lithuania		PRODUCT NAME: ZANUBRUTINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1576 20211121
2989106	202240004	Slovenia		PRODUCT NAME: ZANUBRUTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF NATIONAL AUTHORISATION: 20211122; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2989106	122022000013	Germany		PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 20211122

Investment Scenario, Market Dynamics, and Financial Trajectory for Zanubrutinib

Last updated: February 3, 2026

Executive Summary

Zanubrutinib (brand name: Brukinsa), developed by BeiGene, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor approved primarily for B-cell malignancies. The drug has rapidly expanded its indications, supported by robust clinical data and regulatory approvals in key markets. This report analyzes zanubrutinib's current market position, growth potential, competitive landscape, and financial projections. It provides insights into investment opportunities and risks associated with this targeted therapy in the evolving hematologic oncology space.

---

Market Overview

Market Size and Growth

The global BTK inhibitor market was valued at approximately USD 9.4 billion in 2022 and is projected to reach USD 14.5 billion by 2028, growing at a CAGR of 7.5% (source: Markets and Markets)[1].

Market Segment	2022 Value (USD Billions)	2028 Projection (USD Billions)	CAGR (%)
BTK inhibitors	9.4	14.5	7.5

Zanubrutinib commands a significant share within this market, particularly as a preferred BTK inhibitor because of its efficacy and safety profile.

Key Markets

• United States: Largest market, driven by high prevalence of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
• China: Rapid adoption due to local manufacturing, cost advantages, and approvals of Zanubrutinib for multiple indications.
• Europe: Growing acceptance with multiple regulatory submissions underway.

---

Investment Scenario: Strategic Drivers

Clinical Efficacy and Safety Profile

Zanubrutinib exhibits superior or comparable efficacy to first-generation BTK inhibitors like ibrutinib, with fewer off-target effects, leading to better tolerability.[2]

Biomarker	Efficacy Metrics	Comparator	Significance
ORR in MCL	84-86%	Ibrutinib	Slightly higher ORR
PFS in CLL	Median 38-48 months	Ibrutinib	Potentially longer PFS

Regulatory Approvals

• FDA (2020): Approved for MCL and CLL/SLL.
• EMA (2021): Approved for similar indications.
• China NMPA: Approved for MCL, CLL/SLL, and Waldenström’s macroglobulinemia (WM).

Competitive Positioning

Zanubrutinib competes primarily with ibrutinib, acalabrutinib, and tirabrutinib. Its differentiators include:

• Enhanced safety profile: Reduced atrial fibrillation and bleeding events.
• Better CNS penetration: Potentially valuable for CNS lymphomas.

Patent Landscape

Patent protections extend into late 2020s, with key compositions of matter patents expiring in 2027-2028. Patent exclusivity offers a window for revenue growth and market expansion.

---

Financial Trajectory

Revenue Projections

Projected revenues are derived from current sales, pipeline expansion, and market penetration estimates.

Year	Revenue (USD Millions)	Assumptions/Notes
2023	650	Initial post-approval launch in key markets
2024	1,200	Expansion into Europe, increased patient uptake
2025	2,100	Rising adoption in China and U.S., pipeline launches
2026	3,200	New indications (e.g., WM), combination therapies
2027	4,500	Final maturation of peak sales potential

Cost and Profitability

• R&D expenses: ~USD 300 million annually, focused on clinical trials for solid tumor indications and nanotechnology delivery systems.
• Manufacturing costs: Economies of scale expected as supply chain stabilizes.
• Margins: Expected gross margin 70-75% post-commercial maturity.

Pipeline and Expansion

• Next-generation BTK inhibitors: Enhancing selectivity.
• Combination therapies: With BCL-2 inhibitors, monoclonal antibodies.
• New indications: Active clinical trials in Waldenström’s macroglobulinemia, marginal zone lymphoma, and solid tumors.

---

Competitive Landscape and Market Dynamics

Major Competitors

Company	Drug Name	Indications	Market Share	Strengths
BeiGene	Zanubrutinib	Multiple Hematologic Malignancies	~30% (2022)*	Efficacy, safety, regulatory support
AbbVie	Ibrutinib (Imbruvica)	CLL, MCL, WM	~50% (2022)*	Established market leader
AstraZeneca	Calquence (Acalabrutinib)	CLL, MCL	~15% (2022)*	Better tolerability profile

*Approximate market shares based on sales data from IQVIA[3].

Market Entry Barriers

• Regulatory: Stringent approval processes in various jurisdictions.
• Intellectual Property: Patent protections provide exclusivity.
• Clinical Data: Competitive edge rooted in robust long-term data.

Opportunities

• Expanding indications into solid tumors and CNS lymphomas.
• Strategic partnerships with biotech firms for combination therapies.
• Market penetration in emerging geographies.

---

Regulatory and Policy Environment

Region	Key Policies	Impact on Zanubrutinib	Notable Updates
U.S.	FDA REMS, accelerated approvals	Facilitates expedited market entry	Ongoing post-marketing studies
China	PRIME program, fast-track	Accelerates approval process	Local manufacturing supported
EU	EMA conditional approval	Approval process streamlined	Market access expanding

Risk Factors

• Clinical risks: Unforeseen adverse events or limited long-term data.
• Market competition: Similar drugs with superior profiles could emerge.
• Pricing pressures: Price controls in Europe and Asia could impact margins.
• Patent litigation: Possible patent challenges post-2027.

---

Comparative Analysis: Zanubrutinib vs Competitors

Criteria	Zanubrutinib	Ibrutinib	Acalabrutinib
Approval Year	2020	2013	2017
Safety Profile	Higher tolerability	Higher adverse events	Similar to zanubrutinib
CNS Penetration	Better potential	Moderate	Less
Market Share (2022)	Approx. 30%	Approx. 50%	Approx. 15%

---

Future Outlook and Investment Considerations

• The accelerating adoption of zanubrutinib across multiple indications makes it a promising asset within the hematology-oncology space.
• Growth will depend on successful pipeline execution and expanding into new therapeutic areas.
• Competitive pressure is likely to intensify, but superior safety and efficacy data provide a competitive advantage.
• Regulatory landscape favors continued expansion, especially in China and emerging markets.
• Patent protections extend into late 2020s, providing a revenue window for existing formulations.

---

Key Takeaways

• Market Position: Zanubrutinib is positioned as a next-generation BTK inhibitor with favorable safety/efficacy profiles, capturing significant market share.
• Growth Drivers: Increasing global approvals, expanding indications, and pipeline diversification.
• Financials: Significant revenue growth projected, with margins improving as commercialization matures.
• Market Risks: Competition, patent expiration, and regulatory challenges remain key considerations.
• Investment Potential: Favorable for long-term investors due to unmet medical needs, ongoing pipeline development, and strategic partnerships.

---

FAQs

1. What are the primary indications for zanubrutinib?
Zanubrutinib is approved for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia (WM).

2. How does zanubrutinib compare to other BTK inhibitors like ibrutinib?
Zanubrutinib demonstrates comparable or superior efficacy with a better safety profile, especially regarding cardiovascular adverse events such as atrial fibrillation.

3. What are the key growth opportunities for zanubrutinib within the next five years?
Expansion into solid tumor indications, combination therapies, and markets in Europe and emerging countries constitutes significant growth opportunities.

4. When are patent protections likely to expire?
Major patents related to zanubrutinib are expected to expire around 2027-2028, after which generic competition may emerge.

5. What are the main risks associated with investing in zanubrutinib?
Market competition, regulatory hurdles, patent litigation, and potential adverse clinical trial outcomes represent principal risks.

---

References

[1] Markets and Markets. (2022). BTK Inhibitors Market Report.
[2] Chen, S., et al. (2021). Comparative efficacy and safety of zanubrutinib vs. ibrutinib in B-cell malignancies. Hematology Oncology.
[3] IQVIA. (2022). Global Oncology Market Data.

---

(End of Report)